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Improved surveillance methods are needed to better understand the current hepatitis C virus (HCV) dis-
ease burden and to monitor the impact of prevention and treatment interventions on HCV transmission
dynamics. Sanger sequencing (HCV NS5B, HVR1 and Core-E1-HVR1) and phylogenetics were applied to
samples from individuals diagnosed with HCV in British Columbia, Canada in 2011. This included individ-
uals with two or three sequential samples collected <1 year apart. Patristic distances between sequential
samples were used to set cutoffs to identify recent transmission clusters. Factors associated with trans-
mission clustering were analyzed using logistic regression. From 618 individuals, 646 sequences were
obtained. Depending on the cutoff used, 63 (10%) to 92 (15%) unique individuals were identiﬁed within
transmission clusters of predicted recent origin. Clustered individuals were more likely to be <40 years
old (Adjusted Odds Ratio (AOR) 2.12, 95% CI 1.21–3.73), infected with genotype 1a (AOR 6.60, 95% CI
1.98–41.0), and to be seroconverters with estimated infection duration of <1 year (AOR 3.13, 95% CI
1.29–7.36) or >1 year (AOR 2.19, 95% CI 1.22–3.97).
Conclusion: Systematic application of molecular phylogenetics may be used to enhance traditional
surveillance methods through identiﬁcation of recent transmission clusters.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis C virus (HCV) has infected between 115 and 185 mil-
lion individuals globally (Gower et al., 2014; Mohd Hanaﬁah et al.,
2013). As of December 2013, 73,500 (1.6%) individuals in British
Columbia (BC) were diagnosed as anti-HCV positive (BC Centre
for Disease Control, 2013). About two-thirds of anti-HCV positiveindividuals in BC are baby boomers born between 1945 and
1965. Most were infected decades ago and are at risk of developing
progressive liver disease as they age. HCV-infected British
Columbians have about a 5-fold increased risk of all-cause and
20-fold increased risk of liver-related mortality (Yu et al., 2013).
HCV continues to be transmitted by people who inject drugs
(PWID), who account for >80% of new infections in many countries
(Hajarizadeh et al., 2013; Nelson et al., 2011). Reducing the popu-
lation disease burden will require enhanced screening, engage-
ment into care and treatment as well as the potential use of
treatment-as-prevention to reduce transmission among PWID
(Martin et al., 2013; Smith et al., 2012; Wiessing et al., 2014).
Informing effective public health interventions requires a clear
understanding of the past and ongoing dynamics of viral epi-
demics. Phylogenetic trees constructed from viral sequences allow
the historical relationships between infected individuals in a pop-
ulation to be modeled (Lam et al., 2010; Pybus and Rambaut, 2009;
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sely related infections, can be identiﬁed from phylogenies along
with spatial, epidemiological and temporal information linked to
their expansion (Grabowski and Redd, 2014; Hue et al., 2005;
Lewis et al., 2008; van de Laar et al., 2009). The ability to quantify
mutation rates enables recent transmission clusters to be identi-
ﬁed and characteristics associated with high rates of transmission
to be inferred (Aldous et al., 2012; Poon et al., 2014).
Phylogenetic cluster analyses are widespread in HIV research
and have revealed that early/acute HIV infections play a major role
in driving the epidemic and also that drug-resistant HIV variants
can be transmitted and establish infection (Brenner et al., 2007;
Kaye et al., 2008). HCV phylogenetic analyses have modeled the
expansion of HCV throughout the 20th century in various global
regions and have identiﬁed factors that likely contributed to the
worldwide epidemic (Magiorkinis et al., 2009; Pybus et al., 2003,
2005; Tanaka et al., 2002). HCV phylogenetic cluster analyses have
been used to conﬁrm transmission events originating in health
care settings and to investigate HCV clustering among
HIV-infected individuals, men who have sex with men (MSM)
and in PWID (Danta et al., 2007; Lanini et al., 2010; Oliveira
et al., 2006; Sacks-Davis et al., 2012; Shemer-Avni et al., 2007;
Urbanus et al., 2009; van de Laar et al., 2009). The criteria for deﬁn-
ing transmission clusters differs for both HIV and HCV-based phy-
logenetics but when strict cutoffs are imposed, clusters that
represent more recent transmission events can be identiﬁed.
Tracking recent transmission clusters over time at a population
level may be used to support HCV incidence estimations and to
identify sub-populations at high risk of HCV transmission.
BC’s centralized laboratory testing and consistent use of demo-
graphic identiﬁers enables identiﬁcation of a subset of recent HCV
infections by linking new anti-HCV positive to previous anti-HCV
negative test results. However, most HCV-infected individuals
have no prior testing history, precluding estimation of when
transmission occurred. The aim of this study was to develop a
method for identifying recent transmission clusters in a popula-
tion. The HCV NS5B, core, E1 and HVR-1 regions were sequenced
in a proportion of individuals who tested anti-HCV positive in BC
in 2011. The genetic distances between sequential specimens from
the same individuals collected less than one year apart were used
to assign cutoffs to identify recent phylogenetic transmission
clusters. This study provides a proof-of-principle for applying
molecular phylogenetics to support traditional surveillance meth-
ods through identiﬁcation of recent transmission clusters in a
population.2. Methods
2.1. Study population and design
The BC Public Health Microbiology and Reference Laboratory
performs approximately 95% of HCV serological screening in BC
(Yu et al., 2013). Automated linkage of anti-HCV positive tests with
past results enables identiﬁcation of seroconverters i.e., individuals
who previously tested anti-HCV negative and are anti-HCV positive
on subsequent testing. For seroconverters the estimated infection
duration was deﬁned as the time between the specimen collection
date and the midpoint between an individual’s last negative and
ﬁrst positive anti-HCV test.
Individuals who tested anti-HCV positive in BC in 2011 were
eligible for assessment. Individuals were classiﬁed as: (1) ﬁrst time
positives: individuals who tested positive for the ﬁrst time in 2011
and had no previous testing history; thus, their infection duration
was unknown; (2) past seroconverters: individuals who serocon-
verted prior to 2011 but tested positive again in 2011 and thushad an estimated infection duration of >1 year; and (3) recent sero-
converters: individuals who tested positive for the ﬁrst time in
2011 and had an estimated infection duration of <1 year. The
University of British Columbia Clinical Research Ethics Board
approved this study.
2.2. HCV RNA testing and sequencing
HCV RNAwas extracted from anti-HCV positive serum using the
MagMAX™-96 Viral RNA Isolation kit (Life Technologies, Carlsbad,
CA, USA). HCV viral loads were quantiﬁed using a semi-
quantitative HCV RT-PCR assay (Meng and Li, 2010).
Complementary DNA (cDNA) was synthesized using the
SuperScript VILO™ cDNA Synthesis Kit (Life Technologies). An
828 bp fragment containing a portion of the HCV polymerase
(Non-Structural-5B; NS5B) and a 1514 bp fragment containing
the HCV Core, Envelope-1, hypervariable region-1 (HVR1) and
the beginning of Envelope-2 (E2) were ampliﬁed using Velocity
DNA polymerase (Bioline, London, UK). Amplicons were puriﬁed
using Agencourt Ampure XP beads (Beckman-Coulter,
Mississauga, Ontario) and were Sanger sequenced using the
BigDye Terminator Cycle Sequencing kit (Life Technologies). HCV
RNA extraction, PCR, Sanger sequencing and thermal cycling condi-
tions are described in detail in the Supplementary information.
2.3. Sequence analysis
Sequences were assembled and edited using Geneious v.6.1.7
(Biomatters, Aukland, New Zealand; http://www.geneious.com/).
The NS5B sequences were trimmed to 650 bp. The Core-E2
sequences were trimmed to 920 bp and are referred to hereafter
as Core-HVR1. Samples that had a partial but not a full Core-HVR1
sequence available were trimmed to 100 bp and contained the
HVR1 region. Reference sequences obtained from the Los Alamos
HCV sequence database (hcv.lanl.gov; Kuiken et al., 2005) (see
Supplementary information) were included in the analysis.
Sequences were aligned using MUSCLE (Edgar, 2004) and align-
ments were edited in Geneious. The program jModeltest-2.1.4
(Darriba et al., 2012) was used to determine the nucleotide substi-
tution model that best described the aligned sequences, which
was determined to be the General Time Reversible model with
gamma distributed rate variation among sites and a proportion of
invariable sites. Maximum likelihood phylogenetic trees were gen-
erated using FastTree2 (Price et al., 2010). Path-o-gen v.1.4was used
to estimate the best ﬁtting root for the phylogenetic trees, which
were visualized and annotated using FigTree v.1.4.0 (http://tree.
bio.ed.ac.uk/software/ﬁgtree/).
2.4. Cluster analysis
Phylogenies included sequences from seroconverters who had
sequential HCV positive samples collected <1 year apart. The
patristic distances (i.e., genetic distance between two sequences
in a phylogenetic tree measured in nucleotide substitutions per
site) between these sequential samples represents HCV sequence
evolution expected to occur within one year. Geneious software
was used to determine the patristic distances between each pair
of sequences in a phylogenetic tree, which include the pairwise
intra-person (two sequences from one individual) and the
within-genotype inter-person (two sequences from two different
individuals) distances.
The intra-person distances were used to assign cutoffs that
were applied to phylogenies using a custom python script (Poon
et al., 2014). Sequences from different individuals with patristic
distances falling below these cutoffs were interpreted as transmis-
sion clusters. The lower cutoff was set close to the maximum
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Core-HVR1 and 0.11 for HVR1). A second, higher cutoff was also
assigned that excludes clusters between BC sequences and the
Los Alamos reference sequences (0.020 for NS5B, 0.06 for
Core-HVR1 and 0.15 for HVR1). A sensitivity analysis was per-
formed using a third cutoff (0.022 for NS5B, 0.09 for Core-HVR1
and 0.19 for HVR1). Clusters within phylogenetic trees were man-
ually examined; sequences from clusters that did not group
together with branch support >80% were split into smaller phylo-
genetically linked clusters or excluded from the analysis. Clusters
were visualized using Graphviz v.2.36 (Gansner and North, 1999).
To provide additional validation for the selected patristic dis-
tance cutoffs, six NS5B reference sequences were obtained from
Genbank (Supplementary material) representing three pairs of
conﬁrmed transmission events (2 individuals/transmission)
(Nakayama et al., 2005; Toda et al., 2009). The sampling intervals
between each of the two individuals in the reported transmission
pairs were between 2 weeks and 3 months. At least one individual
from each transmission pair was diagnosed with acute HCV at the
time of sampling i.e., transmission occurred approximately
6 months or less prior to sample collection. A phylogenetic and
cluster analysis using these additional sequences (along with the
BC sequences and Los Alamos reference sequences) was performed
to determine the patristic distances between individuals in trans-
mission pairs.2.5. Statistical analysis
Logistic regression was used to identify factors hypothesized to
be associated with recent infection, including age, sex, HCV geno-
type, seroconversion status, HIV status and geographic location
(Jacka et al., 2014; Miller et al., 2002; Oliveira et al., 2009;
Sacks-Davis et al., 2012). As 84% of sequences were genotypes 1a
and 3a, the remaining genotypes were grouped together for analy-
sis. Age was dichotomized to <40 vs. P40 years since unadjusted
analysis demonstrated that individuals <30, 30–34 and 35–39 years
were more likely to be in clusters than those >61 years (data not
shown). In multivariate analyses, factors that were signiﬁcant at
p < 0.20 in the unadjusted analysis were considered as potential
independent variables associated with clustering. For individuals
with sequential samples, the ﬁrst sample per individual was used.
Analyses were performed in R, version 3.03 (R Core Team, 2013).3. Results
3.1. HCV sequencing
In 2011, of 3356 individuals that tested anti-HCV positive in BC,
51% (n = 1715) were ﬁrst-time anti-HCV positive (unknown infec-
tion duration), 38% (n = 1267) seroconverted between 1993 and
2010 (estimated infection duration >1 year), and 11% (n = 374)
seroconverted in 2011 (132 had an estimated infection duration
<1 year and 242 had an estimated infection duration >1 year).
For this study, 1546 of the 3356 anti-HCV positive samples were
selected for analysis, including: (1) 897 randomly selected samples
from the 1715 ﬁrst time positive individuals; (2) 222 randomly
selected samples from the 1267 seroconverters diagnosed prior
to 2011 (many of whom are likely chronically infected), and (3)
all available samples from 351 of 374 individuals who serocon-
verted in 2011 (283 had one sample and 68 had two or three
sequential samples; total samples = 427) (Fig. 1A).
Of the 1546 samples selected, 1138 (74%) had detectable HCV
RNA (>200 IU/ml), which yielded 646 sequences from 618 individ-
uals (593 NS5B and 415 Core-HVR1) (Fig. 1A). For 52 additional
samples, only a partial Core-HVR1 sequence was available; forthese, the HVR1 sequence alone was examined and compared to
all available HVR1 sequences (n = 466). Of the 68 individuals with
sequential samples, sequences were obtained from 25 individuals.
There were 363 samples that yielded sequences for all three
regions (Fig. 1B). HCV RNA viral load of >20,000 IU/ml and being
a seroconverter were associated with successful sequencing
(Supplementary Table S1). Study subject characteristics are sum-
marized in Table 1.
3.2. HCV phylogenetics
Phylogenies for NS5B, Core-HVR1 and HVR1 were constructed
(Supplementary Figs. S1–S3). As expected, HCV sequences grouped
together by genotype in both the NS5B and Core-HVR1 phyloge-
nies. When HVR1 was examined alone, the majority of sequences
also grouped by genotype, however there were several sequences
that did not group with the predicted genotype. This likely reﬂects
the high heterogeneity of HVR1 and the fact that many mutations
in this region are driven by host immune pressure (Dowd et al.,
2009; Liu et al., 2010). Also apparent from the phylogenetic trees
is that the genotype 1a sequences form two large and distinct phy-
logenetic clusters.
3.3. Identiﬁcation of HCV transmission clusters
Within each phylogeny, the patristic distances between pairs of
intra-person sequential samples were determined and used to set
cutoffs for identifying clusters as described in the Methods.
For NS5B, 593 sequences were obtained from 574 individuals;
17 individuals had sequential samples with a median (interquartile
range) of 75 (21–161) days between sample collections. The
inter-person patristic distances ranged from 0 to 0.35 (median
0.10) (Fig. 2A). Note that the presence of the bimodal hump in
the distribution presented in Fig. 2A reﬂects the presence of the
two genotype 1a phylogenetic groups. The intra-person patristic
distances ranged from 0 to 0.017 (Fig. 2A). Of note, three sequential
samples from one individual from 2009 and 2010 (23–454 days
apart) also had patristic distances between 0 and 0.017. Applying
the lower (0.018) and higher (0.020) cutoffs to the phylogeny iden-
tiﬁed 55 individuals (10%) in 25 clusters and 73 individuals (13%)
in 31 clusters, respectively (Fig. 3A and Table 2).
To provide additional validation, an analysis of three conﬁrmed
transmission pairs using published NS5B sequences was performed
(Nakayama et al., 2005; Toda et al., 2009). The three transmission
pairs were found to cluster with patristic distances of 0.002, 0.006
and 0.01, respectively.
For Core-HVR1, 415 sequences were obtained from 396 individ-
uals; 18 individuals had sequential samples with a median
(interquartile range) of 71.5 (22.5–122) days between sample col-
lections. The inter-person patristic distances ranged from 0.004 to
0.55 (median 0.22) (Fig. 2B). The intra-person patristic distances
ranged from 0.0003 to 0.026 (Fig. 2B). Applying the lower (0.03)
and higher (0.06) cutoffs to the phylogeny identiﬁed 24 individuals
(6%) in 12 clusters and 48 individuals (12%) in 23 clusters, respec-
tively (Fig. 3B and Table 2).
For HVR1, 466 sequences were obtained from 445 individuals;
20 individuals had sequential samples with a median (interquartile
range) of 71.5 (21.5–117.8) days between sample collections. The
inter-person patristic distances ranged from 0.01 to 2.91 (median
0.78) (Fig. 2C). The intra-person patristic distances ranged from 0
to 0.109 (Fig. 2C). Applying the lower (0.15) and higher (0.19) cut-
offs to the phylogeny identiﬁed 19 individuals (4%) in 9 clusters and
31 individuals (7%) in 15 clusters respectively (Fig. 3C and Table 2).
When the sequences for all three regions were combined, 63
(10%; lower cutoffs) and 92 (15%; higher cutoffs) unique individuals
were identiﬁed as belonging to clusters. In all, 27 individuals in 13
A B
Fig. 1. Sequences obtained for HCV NS5B, Core-HVR1 and HVR1 regions. (A) Number of samples extracted, number samples with detectable HCV (>200 IU/ml), and number of
sequences from each HCV genomic region. (B) Distribution of sequences for each of the HCV genomic regions.
Table 1
Characteristics of individuals with available HCV sequences (n = 618).
Characteristic No. of individuals
Sex
Female 202
Male 415
Unknown 1
Age
Mean (SD) 46.2 (12.5)
<40 year 258
P40 year (baby boomers) 360
HCV genotype
1a 393
1b 35
2a 22
2b 37
3a 124
Other 7
BC geographic region
Interior 114
Fraser 207
Vancouver Coastal 140
Vancouver Island 82
Northern 60
Unknown 15
Test group
Recent seroconvertera 52
Past seroconverterb 203
First-time HCV positivec 363
HIV co-infection
Yes 16
No 436
Unknown 166
a Individuals with estimated infection duration <1 year.
b Individuals with estimated infection duration >1 year.
c Individuals with unknown infection duration.
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Core-HVR1 regions (Fig. 3). Of note, 29 ﬁrst time positive individuals
with unknown infection duration were identiﬁed within clusters,
suggesting that they were involved in recent transmission events.3.4. Factors associated with transmission clusters
Factors associated with clustering were examined using the
NS5B region, as this region has the greatest amount of dataavailable. Using unadjusted analysis, factors associated with
NS5B clusters identiﬁed using the higher cutoff (0.02) included
age, HCV genotype 1a and 3a, and being a seroconverter (recent
or past) (Supplementary Table S2). In adjusted analysis, age
<40 years vs. P40 years (Adjusted Odds Ratio (AOR) 2.12, 95% CI
1.21–3.73), genotype 1a infection vs. other genotypes (AOR 6.60,
95% CI 1.98–41.0), and being a recent seroconverter vs. ﬁrst time
positive (AOR 3.13, 95% CI 1.29–7.36) or a past seroconverter vs.
ﬁrst time positive (AOR 2.19, 95% CI 1.22–3.97) were indepen-
dently associated with clustering (Table 3 and Supplementary
Table S2). Unadjusted analysis of NS5B clusters identiﬁed using
the lower cutoff (0.018) yielded similar results to those identiﬁed
using the higher cutoff (Table 3 and Supplementary Table S3). In
the adjusted analysis, genotype 1a and seroconverter status were
independently associated with clustering.
Factors associated with clustering in the Core-HVR1 and HVR1
regions were also analyzed and the results are comparable to those
obtained using NS5B; however, some minor differences were
observed dependent on the region and cutoff examined (Table 3).
In a sensitivity analysis, factors associated with clustering were
similar to those identiﬁed using the higher or lower cutoffs
(Table 3).
4. Discussion
This study demonstrates the feasibility of using sequenced-
based phylogenetics to identify recent HCV transmission clusters,
which could support surveillance of population-level transmission
dynamics. A convenience sample of sequential HCV RNA positive
specimens from individual seroconverters permitted measurement
of the expected intra-person HCV sequence evolution within
1 year. The maximum intra-person patristic distances were used
as cutoffs to identify recent transmission clusters, and a higher cut-
off was also applied to account for greater inter-person sequence
variation that results from a change in host environments and
immune pressures following transmission (Bull et al., 2011;
Kuntzen et al., 2007; Mcallister et al., 1998; Merani et al., 2010).
Using the lower and higher cutoffs, 63–92 unique individuals, were
identiﬁed within clusters. Twenty-nine individuals in clusters were
ﬁrst-time positive testers with unknown infection duration and
their identiﬁcation within clusters indicates their involvement in
a recent transmission event.
Individuals in clusters were more likely to have characteristics
associated with incident infection in PWID (young age,
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et al., 2002; Oliveira et al., 2009; Sacks-Davis et al., 2012) and were
also more likely to have infection duration <1 year, supporting the
hypothesis that individuals in clusters were involved in recent
transmission events. In BC, >80% of seroconverters report injection
drug use as their primary HCV acquisition risk factor. Consistent
with these ﬁndings, a recent study by Jacka et al. (2014) demon-
strated that individuals in clusters from a BC PWID cohort were
more likely to be <40 years and to be seroconverters. These ﬁnd-
ings complement BC surveillance data, which shows that acute
HCV infections are infrequent in baby boomers (Kuo et al., 2015)
and substantiates a lower onward transmission risk in this birth
cohort.
Three regions, the HVR1, Core-HVR1 and NS5B, were examined
because of their different genetic evolutionary rates, which allow
transmissions over different time scales to be examined. Evolution
ofHVR1 is not linear (Mcallister et al., 1998) andmutations accumu-
late rapidly (Dowd et al., 2009; Kuntzen et al., 2007; Liu et al., 2010)
making this region useful for verifying person-to-person transmis-
sions and for monitoring HCV genomic changes over short but not
longer time periods (Escobar-Gutierrez et al., 2012; Weiner et al.,
1993). Use of the highly conserved Core region combined with E1
and HVR1 increases the capacity to identify transmissions that
may not be apparent with HVR1 alone, and as expected, a larger
number of clusters were identiﬁed using Core-HVR1. The NS5B
region evolves at an intermediate and more stable rate, which
allows transmissions over longer timeperiods to be examinedwhilestill supporting identiﬁcation of recent transmission events
(Cavalheiro Nde et al., 2009; Hmaied et al., 2007). The NS5B ampli-
con used for this study was longer than that typically used (650 bp
vs. 380 bp) (Jacka et al., 2013), which may have improved its ability
to identify clusters.
The largest number of clusters was identiﬁed in NS5B and while
many sequences were unavailable for comparison in the other
regions, several NS5B clusters were also observed in HVR1 and/or
Core-HVR1. Identiﬁcation of clusters in two regions provides stron-
ger support for transmission events. Some NS5B clusters had
highly divergent Core-HVR1 or HVR1 sequences, suggesting no
recent transmissions occurred between these individuals. In other
NS5B clusters, the patristic distances between HVR1 and/or
Core-HVR1 sequence pairs were only slightly above the cutoffs,
suggesting that the cutoff in highly variable regions could be
relaxed further to capture additional individuals within a transmis-
sion network. No clusters were identiﬁed between BC samples and
the Los Alamos reference sequences, which supports the stringency
of our method. Additional validation was provided by the use of
conﬁrmed transmission pairs, which were found to cluster in the
NS5B region using the assigned cutoffs. It is important to note that
various factors can inﬂuence the rate of HCV evolution over time
(i.e. acute vs. chronic HCV infection, co-infection with HIV and
immune status (Jabara et al., 2014; Merani et al., 2010;
Ramachandran et al., 2011; Ray et al., 2005)), which will inﬂuence
the patristic distance cutoffs and the identiﬁcation of recent trans-
mission clusters. Future work will further assess the utility of using
Common cluster
Genotype 1a
Genotype 3a
Genotype 2b
A  NS5B Clusters <0.018
B  Core-HVR1 Clusters <0.03
C  HVR1 Clusters <0.11
NS5B Clusters <0.02
Core-HVR1 Clusters <0.06
HVR1 Clusters <0.15
Fig. 3. Transmission clusters. (A) Inter-person (between different individuals) NS5B sequence clusters with patristic distances <0.018 (left) or <0.02 (right). (B) Inter-person
Core-HVR1 sequence clusters (between different individuals) with patristic distances <0.03 (left) or <0.06 (right). (C) Inter-person HVR1 sequence clusters (between different
individuals) with patristic distances <0.11 (left) or <0.15 (right). Nodes represent individual sequences and the connector length is proportional to the patristic distance
between sequences. Common clusters (bold outline) are those that occur in both NS5B and Core-HVR1 or HVR1 alone.
Table 2
Number of clusters and individuals in clusters with various patristic distance cutoffs.
Cutoff Total na n in clusters % clustering Number of clusters
NS5B
0.018 574 55 10 25
0.020 73 13 31
0.022b 82 14 34
Core-HVR1
0.03 415 24 6 12
0.06 48 12 23
0.09b 88 21 38
HVR1
0.11 445 19 4 9
0.15 31 7 15
0.19b 45 10 20
a n = Number of individuals.
b Sensitivity analysis.
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transmission dynamics.
A limitation to this study is that the serum samples used were
collected in 2011 for the purposes of antibody screening, and were
not stored under optimal conditions. For real-time population
studies, these protocols would be applied to fresh serum samples
within a day of collection or to blood samples containing EDTA
to increase HCV RNA integrity, which should improve sequence
yield. A further limitation to this study was the use of the midpoint
between the last negative and ﬁrst positive test date to estimate
infection duration in seroconverters. For HIV, seroconverters iden-
tiﬁed through routine public health screening were more likely to
have been infected closer to the time of the ﬁrst positive test (Skar
et al., 2013). Thus, individuals with long gaps between the lastnegative and ﬁrst positive tests and an estimated HCV infection
duration >1 year may have in fact been infected more recently.
This likely explains, in part, the association between clustering
and being a past seroconverter with infection duration >1 year.
On the other hand, unlike with HIV, it has not been demonstrated
that acute/early infections disproportionately drive HCV transmis-
sion. Many HCV infected individuals go undiagnosed for years or
even decades (Rein et al., 2012; Shah et al., 2013), also HCV viral
loads can remain high and stable throughout the course of infec-
tion, and the majority of HCV infected individuals remain
untreated. This suggests that chronically infected individuals may
be a signiﬁcant source of onward HCV transmission and thus it is
unsurprising that past seroconverters are also linked with trans-
mission clusters.
The cluster analyses presented here cannot be directly extrapo-
lated to create population incidence estimates given that this was a
proof-of-principle study with a selection bias for seroconverters to
maximize the identiﬁcation of transmission clusters. In the future,
these methods may be used, in combination with other strategies
(i.e. tracking seroconverters and using diversity to estimate trans-
mission timing (Montoya et al., 2015)) to obtain a comprehensive
view of HCV incidence in BC. Every year >2000 individuals undergo
HCV genotyping at the BC Centre for Disease Control and it would
be feasible to apply routine sequencing and phylogenetics to these
individuals given the declining cost of sequencing. Implementing
this type of strategy could help to identify a subset of individuals
with recent infection with no prior negative test available. It can
also be used to identify clusters of individuals that are transmitting
HCV and who may be targets for HCV prevention strategies.
This study supports the application of sequencing, phylogenet-
ics, and the use of patristic distance cutoffs to identify recent trans-
mission clusters between HCV infected individuals with unknown
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level and performed on an ongoing basis, may allow monitoring of
HCV transmission networks and the changing dynamics of clusters
over time, i.e. if new clusters arise from pre-existing clusters and if
the number of clusters increases or decreases over time. This in
turn could enable monitoring of transmission patterns in response
to increased HCV screening and treatment uptake. It may also facil-
itate the tracking and evaluation of prevention interventions such
as harm-reduction and treatment-as-prevention.
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